Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Measles-mumps-rubella-varicella vaccine · 1 trial · 5 indications
Solicited injection site reactions: tenderness, Erythema (Redness), and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability
| Arm | Type | Description |
|---|---|---|
| Group 1: Menactra® and Routine Pediatric Vaccines | EXPERIMENTAL | Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate \[PCV\], and hepatitis A \[HepA\]) at age 12 months. |
| Group 2: Routine Pediatric Vaccines | OTHER | Participants received routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate\[PCV\], and hepatitis A \[HepA\]) at age 12 months. |
| Name | Type | Description |
|---|---|---|
| Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, IM at age 9 and 12 months |
| Measles-mumps-rubella-varicella vaccine | BIOLOGICAL | 0.5 mL, intramuscular at 12 months of age |
| Routine paediatric vaccine - Pneumococcal conjugate (PCV) | BIOLOGICAL | 0.5 mL, Intramuscular at age 12 months |
| Routine paediatric vaccine - Hepatitis A | BIOLOGICAL | 0.5 mL, Intramuscular at age 12 months |
Inclusion Criteria : * Healthy, as determined by medical history and physical examination * Aged 9 months (249 to 305 days) or 12 months (365 to 400 days) at the time of enrollment * The parent or legal guardian has signed and dated the Independent Ethics Committee (IEC)-/Institutional Review Board...
Measles-mumps-rubella-varicella vaccine is used for meningococcal meningitis, as well as measles, mumps, rubella, and varicella. It is a monoclonal antibody being developed by Sanofi for infectious disease. The vaccine is currently in Phase 3 clinical development.
Sanofi (ticker: SNY) is developing Measles-mumps-rubella-varicella vaccine. The vaccine is in Phase 3 clinical trials for meningococcal meningitis and other infectious diseases. Sanofi is conducting the development as part of its infectious disease portfolio.
Measles-mumps-rubella-varicella vaccine is in Phase 3 clinical development. It is an investigational vaccine, not yet approved by regulatory authorities. The Phase 3 trial has been completed, with results from 1,378 participants.
Measles-mumps-rubella-varicella vaccine is associated with clinical trial NCT00483574, titled 'Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers.' This Phase 3 trial was completed and enrolled 1,378 participants in the United States and Chile.
Measles-mumps-rubella-varicella vaccine is not the same as Menactra. The clinical trial NCT00483574 studied the safety of Menactra vaccine when administered with other pediatric vaccines, including measles-mumps-rubella-varicella vaccine. They are separate vaccines evaluated together in the trial.